Universität zu Köln

Sasse, Stephanie, Alram, Magdalena, Mueller, Horst, Smardova, Lenka, Metzner, Bernd, Doehner, Hartmut, Fischer, Thomas, Niederwieser, Dietger W., Schmitz, Norbert, Schaefer-Eckart, Kerstin, Raemaekers, John M. M., Schmalz, Oliver, Tresckow, Bastian V., Engert, Andreas and Borchmann, Peter (2016). Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leuk. Lymphoma, 57 (5). S. 1067 - 1074. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). Based on the results of the HDR2 trial two courses of DHAP and subsequent HDCT/ASCT are the current standard of care in relapsed HL. In order to assess the prognostic relevance of DHAP dose density, we performed a retrospective multivariate analysis of the HDR2 trial (N=266). In addition to four risk factors (early or multiple relapse, stage IV disease or anemia at relapse, and grade IV hematotoxicity during the first cycle of DHAP) a delayed start of the second cycle of DHAP>day 22 predicted a significantly poorer progression-free survival (PFS, p=0.0356) and overall survival (OS, p=0.0025). In conclusion, our analysis strongly suggests that dose density of DHAP has a relevant impact on the outcome of relapsed HL patients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Sasse, Stephanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Alram, Magdalena UNSPECIFIED UNSPECIFIED UNSPECIFIED Mueller, Horst UNSPECIFIED UNSPECIFIED UNSPECIFIED Smardova, Lenka UNSPECIFIED UNSPECIFIED UNSPECIFIED Metzner, Bernd UNSPECIFIED UNSPECIFIED UNSPECIFIED Doehner, Hartmut UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Niederwieser, Dietger W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmitz, Norbert UNSPECIFIED UNSPECIFIED UNSPECIFIED Schaefer-Eckart, Kerstin UNSPECIFIED UNSPECIFIED UNSPECIFIED Raemaekers, John M. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmalz, Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED Tresckow, Bastian V. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-290220
DOI:	10.3109/10428194.2015.1083561
Journal or Publication Title:	Leuk. Lymphoma
Volume:	57
Number:	5
Page Range:	S. 1067 - 1074
Date:	2016
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1029-2403
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; CHEMOTHERAPY; DISEASE; CHEMORADIOTHERAPY; INTENSITY; SALVAGE; BEACOPP; ABVD Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/29022